ABAndrew Michael Beekman

Andrew Michael Beekman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew Michael Beekman has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peptide-Directed Ligand Design Enables Chemical Disruption of the Nrf2/MafG Coiled-Coil Transcription Factor Complex.

    by Ellen E. Hyde, Emily Hobson, Owen Mullen, Zoë R. Goddard, Sean Tattan, Marco M.D. Cominetti, Mark Searcey, Maria A. O’COnnell, Andrew M. Beekman

    Transcription factor protein interactions remain among the most challenging targets in chemical biology, particularly those driven by leucine zipper coiled coil assemblies. For this challenge we developed a peptide-directed ligand design strategy identifying inhibitors of the Nrf2/MafG transcription factor complex, a key driver of cytoprotective signalling and cancer chemoresistance. MafG-derived α-helical peptides bind Nrf2 and disrupt formation of the Nrf2/MafG/DNA complex. Guided by structural modelling, peptide-small molecule hybrids were subsequently developed that preserved inhibitory activity while reducing peptide content. Lead hybrids inhibited Nrf2/MafG/DNA assembly, suppressed Nrf2-dependent transcriptional responses, reduced HO-1 and NQO1 gene expression, NQO1 enzymatic activity, and decreased nuclear localisation of Nrf2 in A549 cells. Disruption of Nrf2/MafG signalling restored sensitivity to gemcitabine in an intrinsically chemoresistant lung cancer model. This provides a new approach for the modulation of coiled-coil transcription factor interactions and new chemical probes for Nrf2-dependent chemoresistance in cancer biology.

  • Open Access

    Protein–protein interaction inhibitors in the human proteome: lessons from 117 targeted interactions

    by Ellen E. Hyde, Andrew M. Beekman

    How does PPI structure influence inhibitor discovery? Analysis of the 117 inhibited human PPIs reveals clear relationships between interface architecture, inhibitor modality and successful discovery strategies.

  • Open Access

    A secreted citrus protease cleaves an outer membrane protein of the Huanglongbing pathogen

    by Alexander J. McClelland, Bin Hu, Yuantao Xu, Xiaodong Fang, Chunxia Wang, Benjamin L. Koch, Amelia H. Lovelace, Eva Hawara, Yuanchun Wang, Zhiqian Pang, et al.

    Plants secrete a variety of proteases as a defense response during infection by microbial pathogens. However, the relationship between their catalytic activities and antimicrobial functions remains largely unknown. Particularly, few biologically relevant substrates of these proteases have been identified. Huanglongbing (HLB) has been a major threat to the citrus industry worldwide. The HLB-associated bacterium, “ Candidatus Liberibacter asiaticus” (Las), was previously shown to deploy an inhibitor of papain-like cysteine proteases (PLCPs) to promote disease in citrus. In this study, we identified an outer membrane protein (OMP) of Las, LasOMP1, as a substrate of the citrus PLCP Cs RD21a. LasOMP1 is one of the most highly expressed genes in Las. Cs RD21a cleaves LasOMP1 and produces cleaved peptide products, which could be detected in vitro and in HLB-diseased citrus plants. We found that Cs RD21a targets the N-terminal portion of LasOMP1, potentially at an extracellular loop region. Importantly, transgenic sweet orange overexpressing Cs RD21a showed reduced Las populations and improved plant growth, highlighting that engineering this protease is a promising strategy to enhance HLB resistance in citrus. Together, our work reveals a pathogen-derived substrate of plant PLCPs and suggests bacterial OMPs may be direct targets of plant defense.


  • Open Access

    Structure-based peptide design identifies inhibitors of the dyskerin/dyskerin interaction in H/ACA ribonucleoproteins targeting brain tumour cell lines

    by Suzanne van Wier, Zoe Goddard, Xiufen Lei, Ellen Hyde, Daniel Picard, Emily Hobson, Marco Cominetti, Maria O'COnnell, Mark Searcey, Marc Remke, et al.

    H/ACA ribonucleoparticles (RNPs) play key regulatory roles in ribosome biogenesis, splicing, and telomerase maintenance and their activities are enhanced in cancer cells. The central component of H/ACA RNPs is the enzyme dyskerin (DKC1). DKC1 has high expression in multiple tumour types, and contributes to cancer hallmarks, tumour growth and cellular immortalization. DKC1 mutations also cause dyskeratosis congenita, a premature-ageing syndrome characterised by hindered ribosome biogenesis and shortened telomeres. We leveraged genetic information to devise a strategy to generate dyskerin inhibitors. Mapping of DKC1 mutations on the cryo-EM structures of H/ACA RNP showed they alter the dyskerin/dyskerin protein-protein interaction in this complex. Based on this, we designed and synthesised peptides that inhibit dyskerin dimerization and developed in vitro protein assays demonstrating protein engagement and interaction inhibition. Lead peptides were tested in brain tumour cells (medulloblastoma and glioblastoma) and caused alterations in cell growth, viability, apoptosis, protein synthesis and snoRNA and telomerase RNA (hTERT) levels. These results suggest for the first time that inhibition of the protein interactions within the H/ACA RNP offers a new target for cancer treatment.

  • Open Access

    Crossing the Divide: A Transitional Undergraduate Research Project in Medicinal Chemistry

    by L. Palmer, A. Beekman, A. Ganesan, S. MacDonald, R. Hatley, P. J. McDermott

    This qualitative case study describes the development, delivery, and review of an undergraduate research experience focused on developing research skills. We share some effective methods for delivering this type of course having designed a lab-based module that is supported by theoretical workshops to introduce students to research and help bridge the gap between undergraduate laboratory training and research. We have designed an assessment framework that focuses on assessing the process, rather than the product. Evaluation of this module with qualitative research methods has highlighted its effectiveness, and some areas for improvement, providing a framework for deployment in other programs looking to arrange undergraduate research experiences.

  • Open Access

    Peptide design to control protein–protein interactions

    by Suzanne P. van Wier, Andrew M. Beekman

    Targeting of protein–protein interactions has become of huge interest in every aspect of medicinal and biological sciences.


  • Open Access

    Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction

    by Deanne Hayward, Zoë R. Goddard, Marco M. D. Cominetti, Mark Searcey, Andrew M. Beekman

    A photoswitch peptide that binds to PD-1/PD-L1 only in the cis conformation, allowing for external control of the immune checkpoint interaction.


  • Open Access

    Borylation via iridium catalysed C–H activation: a new concise route to duocarmycin derivatives

    by Marco M. D. Cominetti, Zoë R. Goddard, Bethany R. Hood, Andrew M. Beekman, Maria A. O'COnnell, Mark Searcey

    A concise synthesis of an alkylation subunit of the duocarmycins is achieved via a C–H-activation approach. The ethyl ester analogue of duocarmycin SA can be made in eleven linear steps from a commercially available precursor.

  • Open Access

    Carbonyl Reductase 1: a novel regulator of blood pressure in Down Syndrome

    by Alexandra J Malbon, Alicja Czopek, Andrew M Beekman, Zoë R Goddard, Aileen Boyle, Jessica R Ivy, Kevin Stewart, Scott Denham, Joanna P Simpson, Natalie Z Homer, et al.

    Background: Approximately one in every 800 children is born with the severe aneuploid condition of Down Syndrome (DS), a trisomy of chromosome 21. Low blood pressure (hypotension) is a common condition associated with DS and can have a significant impact on exercise tolerance and quality of life. Little is known about the factors driving this hypotensive phenotype and therefore therapeutic interventions are limited. Carbonyl reductase 1 (CBR1) is an enzyme contributing to the metabolism of prostaglandins, glucocorticoids, reactive oxygen species and neurotransmitters, encoded by a gene ( CBR1 ) positioned on chromosome 21 with potential to impact blood pressure. Methods: Utilising genetically modified mice and telemetric blood pressure measurement, we tested the hypothesis that CBR1 influences blood pressure and that its overexpression contributes to hypotension in DS. Results: In a mouse model of DS (Ts65Dn), which exhibit hypotension, CBR1 activity was increased and pharmacological inhibition of CBR1 increased blood pressure. Mice heterozygous null for Cbr1 had reduced CBR1 enzyme activity and elevated blood pressure. Further experiments indicate that the underlying mechanisms include alterations in sympathetic tone and prostaglandin metabolism. Conclusions: We conclude that CBR1 activity contributes to blood pressure homeostasis and inhibition of CBR1 may present a novel therapeutic opportunity to correct symptomatic hypotension in DS.

  • Open Access

    Borylation via Iridium catalysed C-H activation: a new concise route to duocarmycin derivatives

    by Marco Cominetti, Zoe Goddard, Bethany Hood, Andrew Beekman, Maria O'COnnell, Mark Searcey

    The synthesis of the ethyl ester analogue of the ultapotent antitumour antibiotic seco-duocarmycin SA has been achieved in eleven linear steps from commercially available starting materials. The DSA alkylation subunit can be made in ten linear steps from the same precursor. The route involves CH activation at the equivalent of the C7 position on indole leading to a borylated intermediate 9 that is stable enough for coupling reactions but can be easily converted to the free hydroxyl analogue.